# Xilio Therapeutics (XLO) — Earnings

XLO · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/xlo/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2025 |
| Period end | Jun 30, 2025 |
| EPS actual | −$2.24 |
| EPS estimate | −$1.10 |
| EPS surprise | −103.05% |
| Revenue surprise | −1.46% |
| Revenue | $8.1M |
| Revenue estimate | $8.2M |
| Reported | Aug 14, 2025 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1840233/000155837025011477/xlo-20250630x10q.htm) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2025 | Aug 14, 2025 | −$1.10 | −$2.24 | -103.05% | $8.2M | $8.1M |
| Q1 2025 | May 8, 2025 | −$2.70 | −$2.52 | 6.59% | $4.4M | $2.9M |
| Q4 2024 | Mar 11, 2025 | −$3.03 | −$2.80 | 7.71% | $3.3M | $1.7M |
| Q3 2024 | Nov 7, 2024 | −$3.45 | −$3.08 | 10.81% | $3.3M | $2.3M |
| Q2 2024 | Aug 8, 2024 | −$3.22 | −$3.36 | -4.35% | $30.0M | $2.4M |
| Q1 2024 | May 14, 2024 | −$1.54 | −$8.68 | -463.64% | $30.0M | — |
| Q4 2023 | Apr 1, 2024 | −$8.72 | −$8.96 | -2.81% | — | — |
| Q3 2023 | Nov 9, 2023 | −$11.31 | −$8.54 | 24.46% | — | — |
| Q2 2023 | Aug 14, 2023 | −$12.15 | −$9.80 | 19.31% | — | — |
| Q1 2023 | May 9, 2023 | −$12.39 | −$11.62 | 6.21% | — | — |
| Q4 2022 | Mar 2, 2023 | −$10.99 | −$11.48 | -4.46% | — | — |
| Q3 2022 | Nov 9, 2022 | −$12.29 | −$10.08 | 17.95% | — | — |
| Q2 2022 | Aug 9, 2022 | −$10.96 | −$12.60 | -15.02% | — | — |
| Q1 2022 | May 12, 2022 | −$14.11 | −$10.92 | 22.62% | — | — |
| Q4 2021 | Mar 1, 2022 | −$15.57 | −$13.72 | 11.87% | — | — |
| Q3 2021 | Dec 2, 2021 | −$15.21 | −$297.78 | -1857.37% | — | — |

## Frequently Asked Questions

### When did Xilio Therapeutics (XLO) last report earnings?

Xilio Therapeutics last reported on Aug 14, 2025, covering fiscal Q2 2025.

### Did XLO beat earnings estimates?

No. Xilio Therapeutics reported EPS of −$2.24 for Q2 2025 against a −$1.10 estimate — a 103.05% miss.

### How much revenue did XLO report last quarter?

Xilio Therapeutics reported $8.1M in revenue for Q2 2025, against a consensus estimate of $8.2M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).